Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.
BACKGROUND
Peroxisome proliferator activated receptor gamma (PPARgamma) involvement in thyroid tumorigenesis has recently been studied, especially in follicular neoplasms. Conflicting results concerning the regulation of this receptor in human papillary carcinoma have been reported. Therefore, we quantitatively assessed PPARgamma immunohistochemical expression in papillary carcinoma in comparison with other types of thyroid tumors and we evaluated its relationship with clinical criteria of aggressiveness.


METHODS
Immunohistochemistry (IHC) was performed on 56 human thyroid papillary carcinomas (PTC), 9 follicular carcinomas (FTC), 20 follicular adenomas (FA) and 18 Hürthle cells adenomas. PTC were divided into subgroups according to some aggressiveness criteria: tumor size, capsular invasion, lymph node metastasis. Immunostaining was semi-quantitatively analyzed using image analysis software.


RESULTS
Strong nuclear PPARgamma expression was detected in a large number of PTC (42%), similar to that found in FTC (44%) or FA (63%). Only Hürthle cell adenoma showed a significantly lower proportion of PPARgamma-positive immunoreactivity (11%, p<0.05). Cases of PTC-associated lymph node metastasis showed a higher percentage of PPARgamma-positivity than other case categories (63% vs. 20%), a result which was also noticed when comparing large PTC with infracentimentric tumors (60% vs. 39%, p<0.05).


CONCLUSIONS
These results, combined with recently published data, suggest that the intense PPARgamma immunostaining revealed in PTC could be related to high wtPPARgamma gene levels. Moreover, they corroborate a strong relationship between PPARgamma expression and tumor progression. PPARgamma IHC evaluation is not a valuable differential diagnostic tool for thyroid tumors but it could be a reliable marker of papillary carcinoma aggressiveness and a potential predictor for an eventual therapy by PPARgamma agonists.
Department of Endocrinology, Bellevue Hospital, St-Etienne University Hospital Center, Saint-Etienne, France.
Bogdan
B
Galusca
Jean Marc
JM
Dumollard
Marie Laure
ML
Chambonniere
Natacha
N
Germain
Jean Michel
JM
Prades
Michel
M
Péoc'h
Bruno
B
Estour
D000236:Adenoma / Q000378:metabolism / Q000473:pathology; D018249:Adenoma, Oxyphilic / Q000378:metabolism / Q000473:pathology; D002291:Carcinoma, Papillary / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D018160:Receptors, Cytoplasmic and Nuclear / Q000096:biosynthesis*; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000473:pathology*; D014157:Transcription Factors / Q000096:biosynthesis*
D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors